Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4182955 | L'Encéphale | 2008 | 5 Pages |
Abstract
The rapid onset of clinical efficacy and the safety profile of etifoxine might be of major interest in the management of ADA as an alternative to conventional anxiolytic treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
N. Besnier, O. Blin,